1 / 6

Assoc.prof . Maija Radzina, R ī ga Stradi ņš U niversity , Radiology Research laboratory

44 Sc production with 18 MeV cyclotron and joint study of scandium-labeled peptide based ligands for clinical use. Assoc.prof . Maija Radzina, R ī ga Stradi ņš U niversity , Radiology Research laboratory Mg.chem . Edgars Mamis, R ī ga Stradi ņš U niversity , Nuclear M edicine Clinic.

hjimenez
Download Presentation

Assoc.prof . Maija Radzina, R ī ga Stradi ņš U niversity , Radiology Research laboratory

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 44Sc production with 18 MeV cyclotron and jointstudy of scandium-labeled peptide based ligands for clinical use Assoc.prof. Maija Radzina, RīgaStradiņšUniversity,Radiology Research laboratory Mg.chem. Edgars Mamis, RīgaStradiņšUniversity,Nuclear MedicineClinic

  2. Aimoftheproject – jointreserachactivity • The goalsof this project are: • To develop economically efficient middle energy (18 MeV) cyclotronbasedtechnology for production and purification of 44Sc radionuclide as a medical diagnostic isotope in comparison with generator based technology • To provide clinical study platform for 44Sc radionuclide based imaging in neuroendocrine tumors • Theranostic pairing – 44Sc + 47Sc and their validation in middle energy cyclotron based technology

  3. DevelopmentoftechnologyDevelopeconomicaly efficient cyclotron manufactured 44Sc as a diagnostic radionuclide and labeling technique • 44Sc liquid andsolid target design and adjustment for 44Sc production with 18 MeV cyclotron; • Production and optimization of 44Sc production using solid target versus using liquid target; • Transfer of crude 44Sc from cyclotron to “hot lab” from solid target versus from liquid target;

  4. Obtain pure, non-carrier added 44Sc by chemical purification versusmass separation with the help of MEDICIS; • Quality check of cyclotron-produced and purified 44Sc against reference sample of 44Sc from MEDICIS; • Developtechnologyandmethod for radiolabeling ofDOTA conjugated peptide (TOC & TATE)with44Sc.Productpurification and formulation; • Quality control – physical and chemical analysis of 44Sc-DOTA conjugated peptide-based ligand for cancer diagnostics; Phase I activities maybe initiated by thebeginning of 2019

  5. JointClinicalresearchplatformVerification of use in clinicalmedicine – 2020/2021 • neuroendocrinetumourpatients for clinical validation of 44Sc-DOTATOC • Unknownprimary NEN • Stage 3 and 4 NEN • licencedmedical PET/CT facility of RSU Nuclear medicine clinic is able to perform in-human imaging studies and host the clinical study with 44Sc- DOTA peptides and cancer binding active substances on a neuroendocrine malignancy patient cohort for the proof of concept • InterestforTheranosticpairing – 44Sc + 47Sc and their validation in neuroendocrine tumors and possibly other malignancy groups

More Related